Use of cookies and trackers

Samsung Bioepis Co., Ltd. today announced the launch of OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea1 (aflibercept), across Europe, starting today. OPUVIZ marks the fifth biosimilar product to be directly commercialized by Samsung Bioepis. It builds on other key biosimilar milestones in Europe this year, including the initiation of direct commercialization of BYOOVIZ™ (ranibizumab) 10 mg/mL solution for injection in a vial, as well as the launch of XBRYK™ ...

Capvidia, a provider of Model-Based Definition (MBD), Model-Based Enterprise (MBE), and CAD interoperability software, today announced Capvidia 2026 R1, the latest version of its software portfolio for manufacturers, OEMs, suppliers, and quality organizations. Built with more than 5,600 development hours, Capvidia 2026 R1 includes a combination of over 400 new features, improvements, customer-requested enhancements, and bug fixes across the Capvidia product portfolio. The release helps manufa...

Alpaca, a global leader in brokerage infrastructure APIs, today announced that it has completed the process to passport its regulated and localized investment services across 29 countries in the EEA (European Economic Area) through its Spain-based EEA hub. The completion of EEA passporting enables Alpaca to extend the regulatory foundation established through its European entity, which is authorized and registered with Spain’s Comisión Nacional del Mercado de Valores (CNMV), across the EEA un...